<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="letter" dtd-version="2.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRS</journal-id>
<journal-id journal-id-type="hwp">spjrs</journal-id>
<journal-id journal-id-type="nlm-ta">Royal Society of Medicine</journal-id>
<journal-title>Journal of the Royal Society of Medicine</journal-title>
<issn pub-type="ppub">0141-0768</issn>
<issn pub-type="epub">1758-1095</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0141076813496235</article-id>
<article-id pub-id-type="publisher-id">10.1177_0141076813496235</article-id>
<article-categories>
    <subj-group subj-group-type="heading">
<subject>Letters</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The law of unintended consequences</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western"><surname>Sundar</surname><given-names>S</given-names></name>
<xref ref-type="corresp" rid="corresp1-0141076813496235"/>
</contrib>
</contrib-group>
<aff id="aff1-0141076813496235">Consultant Oncologist Nottingham University Hospitals NHS trust Nottingham NG5 1PB</aff>
<author-notes>
<corresp id="corresp1-0141076813496235">Email: <email xlink:type="simple">sundar@oncology.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>106</volume>
<issue>8</issue>
<fpage seq="a">303</fpage>
<lpage>303</lpage>
<permissions>
<copyright-statement>Â© The Royal Society of Medicine</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The Royal Society of Medicine</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>The medical innovation bill being proposed by Lord Saatchi is laudable in its intentions.<sup><xref ref-type="bibr" rid="bibr1-0141076813496235">1</xref></sup> But the medical innovation bill runs the risk of further embedding the practice of defensive medicine by setting out even more legal criteria that could expand the scope of legally defined medical negligence.</p>
<p>Furthermore, the distinction between clinical research with no direct benefit to patient and innovative treatment intended to benefit the patient is an artificial one. Hence, the laudable aims of medical innovation bill are likely to run foul of the EU clinical trials directive.</p>
<p>The EU clinical trials directive, which initially set out with the commendable aims of promoting research and protecting patients, ended up stifling academically led, innovative, cutting edge research. The mountains of paperwork essential for demonstrating compliance with EU clinical trials directive choked off the seeds of innovation.<sup><xref ref-type="bibr" rid="bibr2-0141076813496235">2</xref>,<xref ref-type="bibr" rid="bibr3-0141076813496235">3</xref></sup></p>
<p>The cancer researchers would be grateful if Lord Saatchi and peers could devote their energies to removing the yoke of EU directive on small, academically led, innovative studies.</p>
</body>
<back>
<sec id="sec1-0141076813496235"><title>Competing interests</title>
<p>None declared</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-0141076813496235"><label>1</label><nlm-citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Saatchi</surname><given-names>M</given-names></name></person-group><article-title>How can an act of parliament cure cancer?</article-title><source>J R Soc Med</source><year>2013</year><volume>106</volume><fpage>169</fpage><lpage>70</lpage></nlm-citation></ref>
<ref id="bibr2-0141076813496235"><label>2</label><nlm-citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Hemminki</surname><given-names>A</given-names></name><name name-style="western"><surname>Kellokumpu-Lehtinen</surname><given-names>PL</given-names></name></person-group><article-title>Harmful impact of EU clinical trials directive</article-title><source>BMJ</source><year>2006</year><volume>4</volume><fpage>332:501</fpage><lpage>2</lpage></nlm-citation></ref>
<ref id="bibr3-0141076813496235"><label>3</label><nlm-citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Hartmann</surname><given-names>M</given-names></name></person-group><article-title>Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries</article-title><source>Trials</source><year>2012</year><volume>13</volume><fpage>53</fpage></nlm-citation></ref></ref-list>
</back>
</article>